Estudo randomizado | Ivermectina não evita hospitalização em pacientes com COVID-19.

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial – BMC Infectious Diseases

Comentário: Ivermectin: balance of evidence shows no significant benefit against Covid-19 – MSN News

Relacionado: Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”. E Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”. E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19